Cargando…
Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial
OBJECTIVES: To evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO). DESIGN, SETTING, AND PATIENTS: Phase IV, prospective, open-label, single-arm trial in 11 Spanish hospitals. Treatment-...
Autores principales: | Garcia-Arumi, Jose, Gómez-Ulla, Francisco, Amparo, Navea, Cervera, Enrique, Fonollosa, Alex, Arias, Luis, Araiz, Javier, Donate, Juan, de Figueroa, Marta Suárez, Manzanas, Lucia, Crespí, Jaume, Gallego, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204200/ https://www.ncbi.nlm.nih.gov/pubmed/30405907 http://dx.doi.org/10.1155/2018/8310350 |
Ejemplares similares
-
Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
por: García-Layana, Alfredo, et al.
Publicado: (2015) -
Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
por: Kim, Yu Cheol, et al.
Publicado: (2020) -
Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO
por: Tang, Fen, et al.
Publicado: (2019) -
Comment on: Ranibizumab and aflibercept intravitreal injection for treatment
naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020) -
Materials with the CrVO(4) structure type as candidate superprotonic conductors
por: Wisesa, Pandu, et al.
Publicado: (2019)